3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 15,533 as of Tuesday, July 30, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,505 issues advancing vs. 1,392 declining with 116 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Bristol-Myers Squibb Company ( BMY), up 0.7%. Top gainers within the industry include Celgene Corporation ( CELG), up 1.6%, Pfizer ( PFE), up 0.6% and Amgen ( AMGN), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Dr. Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dr. Reddy Laboratories is down $1.66 (-4.4%) to $36.22 on average volume. Thus far, 95,121 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 216,900 shares. The stock has ranged in price between $35.97-$36.32 after having opened the day at $36.10 as compared to the previous trading day's close of $37.88.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $6.7 billion and is part of the health care sector. Shares are up 13.8% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Dr. Reddy Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Novo Nordisk A/S ( NVO) is down $1.43 (-0.8%) to $167.09 on light volume. Thus far, 82,514 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 301,200 shares. The stock has ranged in price between $167.04-$168.92 after having opened the day at $168.64 as compared to the previous trading day's close of $168.52.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $92.3 billion and is part of the health care sector. Shares are up 3.3% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.35 (-0.9%) to $39.55 on heavy volume. Thus far, 3.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $38.93-$39.77 after having opened the day at $39.03 as compared to the previous trading day's close of $39.90.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.7 billion and is part of the health care sector. Shares are up 9.1% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%